Immunomodulatory Activity of the Tyrosine Kinase Inhibitor Dasatinib to Elicit NK Cytotoxicity against Cancer, HIV Infection and Aging
Tyrosine kinase inhibitors (TKIs) have been extensively used as a treatment for chronic myeloid leukemia (CML). Dasatinib is a broad-spectrum TKI with off-target effects that give it an immunomodulatory capacity resulting in increased innate immune responses against cancerous cells and viral infecte...
| Main Authors: | , , , , , |
|---|---|
| Format: | Article |
| Language: | English |
| Published: |
MDPI AG
2023-03-01
|
| Series: | Pharmaceutics |
| Subjects: | |
| Online Access: | https://www.mdpi.com/1999-4923/15/3/917 |
| _version_ | 1797609490153996288 |
|---|---|
| author | Andrea Rodríguez-Agustín Víctor Casanova Judith Grau-Expósito Sonsoles Sánchez-Palomino José Alcamí Núria Climent |
| author_facet | Andrea Rodríguez-Agustín Víctor Casanova Judith Grau-Expósito Sonsoles Sánchez-Palomino José Alcamí Núria Climent |
| author_sort | Andrea Rodríguez-Agustín |
| collection | DOAJ |
| description | Tyrosine kinase inhibitors (TKIs) have been extensively used as a treatment for chronic myeloid leukemia (CML). Dasatinib is a broad-spectrum TKI with off-target effects that give it an immunomodulatory capacity resulting in increased innate immune responses against cancerous cells and viral infected cells. Several studies reported that dasatinib expanded memory-like natural killer (NK) cells and γδ T cells that have been related with increased control of CML after treatment withdrawal. In the HIV infection setting, these innate cells are associated with virus control and protection, suggesting that dasatinib could have a potential role in improving both the CML and HIV outcomes. Moreover, dasatinib could also directly induce apoptosis of senescence cells, being a new potential senolytic drug. Here, we review in depth the current knowledge of virological and immunogenetic factors associated with the development of powerful cytotoxic responses associated with this drug. Besides, we will discuss the potential therapeutic role against CML, HIV infection and aging. |
| first_indexed | 2024-03-11T06:02:04Z |
| format | Article |
| id | doaj.art-4dfb007b97b4404b9d45ed171b22e5db |
| institution | Directory Open Access Journal |
| issn | 1999-4923 |
| language | English |
| last_indexed | 2024-03-11T06:02:04Z |
| publishDate | 2023-03-01 |
| publisher | MDPI AG |
| record_format | Article |
| series | Pharmaceutics |
| spelling | doaj.art-4dfb007b97b4404b9d45ed171b22e5db2023-11-17T13:16:13ZengMDPI AGPharmaceutics1999-49232023-03-0115391710.3390/pharmaceutics15030917Immunomodulatory Activity of the Tyrosine Kinase Inhibitor Dasatinib to Elicit NK Cytotoxicity against Cancer, HIV Infection and AgingAndrea Rodríguez-Agustín0Víctor Casanova1Judith Grau-Expósito2Sonsoles Sánchez-Palomino3José Alcamí4Núria Climent5HIV Unit, Hospital Clínic-IDIBAPS, University of Barcelona, 08036 Barcelona, SpainHIV Unit, Hospital Clínic-IDIBAPS, University of Barcelona, 08036 Barcelona, SpainHIV Unit, Hospital Clínic-IDIBAPS, University of Barcelona, 08036 Barcelona, SpainHIV Unit, Hospital Clínic-IDIBAPS, University of Barcelona, 08036 Barcelona, SpainCIBER of Infectious Diseases (CIBERINFEC), 28029 Madrid, SpainHIV Unit, Hospital Clínic-IDIBAPS, University of Barcelona, 08036 Barcelona, SpainTyrosine kinase inhibitors (TKIs) have been extensively used as a treatment for chronic myeloid leukemia (CML). Dasatinib is a broad-spectrum TKI with off-target effects that give it an immunomodulatory capacity resulting in increased innate immune responses against cancerous cells and viral infected cells. Several studies reported that dasatinib expanded memory-like natural killer (NK) cells and γδ T cells that have been related with increased control of CML after treatment withdrawal. In the HIV infection setting, these innate cells are associated with virus control and protection, suggesting that dasatinib could have a potential role in improving both the CML and HIV outcomes. Moreover, dasatinib could also directly induce apoptosis of senescence cells, being a new potential senolytic drug. Here, we review in depth the current knowledge of virological and immunogenetic factors associated with the development of powerful cytotoxic responses associated with this drug. Besides, we will discuss the potential therapeutic role against CML, HIV infection and aging.https://www.mdpi.com/1999-4923/15/3/917dasatinibtyrosine kinase inhibitorsCMLcancerHIV-1CMV |
| spellingShingle | Andrea Rodríguez-Agustín Víctor Casanova Judith Grau-Expósito Sonsoles Sánchez-Palomino José Alcamí Núria Climent Immunomodulatory Activity of the Tyrosine Kinase Inhibitor Dasatinib to Elicit NK Cytotoxicity against Cancer, HIV Infection and Aging Pharmaceutics dasatinib tyrosine kinase inhibitors CML cancer HIV-1 CMV |
| title | Immunomodulatory Activity of the Tyrosine Kinase Inhibitor Dasatinib to Elicit NK Cytotoxicity against Cancer, HIV Infection and Aging |
| title_full | Immunomodulatory Activity of the Tyrosine Kinase Inhibitor Dasatinib to Elicit NK Cytotoxicity against Cancer, HIV Infection and Aging |
| title_fullStr | Immunomodulatory Activity of the Tyrosine Kinase Inhibitor Dasatinib to Elicit NK Cytotoxicity against Cancer, HIV Infection and Aging |
| title_full_unstemmed | Immunomodulatory Activity of the Tyrosine Kinase Inhibitor Dasatinib to Elicit NK Cytotoxicity against Cancer, HIV Infection and Aging |
| title_short | Immunomodulatory Activity of the Tyrosine Kinase Inhibitor Dasatinib to Elicit NK Cytotoxicity against Cancer, HIV Infection and Aging |
| title_sort | immunomodulatory activity of the tyrosine kinase inhibitor dasatinib to elicit nk cytotoxicity against cancer hiv infection and aging |
| topic | dasatinib tyrosine kinase inhibitors CML cancer HIV-1 CMV |
| url | https://www.mdpi.com/1999-4923/15/3/917 |
| work_keys_str_mv | AT andrearodriguezagustin immunomodulatoryactivityofthetyrosinekinaseinhibitordasatinibtoelicitnkcytotoxicityagainstcancerhivinfectionandaging AT victorcasanova immunomodulatoryactivityofthetyrosinekinaseinhibitordasatinibtoelicitnkcytotoxicityagainstcancerhivinfectionandaging AT judithgrauexposito immunomodulatoryactivityofthetyrosinekinaseinhibitordasatinibtoelicitnkcytotoxicityagainstcancerhivinfectionandaging AT sonsolessanchezpalomino immunomodulatoryactivityofthetyrosinekinaseinhibitordasatinibtoelicitnkcytotoxicityagainstcancerhivinfectionandaging AT josealcami immunomodulatoryactivityofthetyrosinekinaseinhibitordasatinibtoelicitnkcytotoxicityagainstcancerhivinfectionandaging AT nuriacliment immunomodulatoryactivityofthetyrosinekinaseinhibitordasatinibtoelicitnkcytotoxicityagainstcancerhivinfectionandaging |